Deciphering signaling pathway interplay via miRNAs in malignant pleural mesothelioma

Pathology Research and Practice 2023 December [Link]

Aya Salman, Sherif S Abdel Mageed, Doaa Fathi, Mahmoud A Elrebehy, Ahmed I Abulsoud, Shereen Saeid Elshaer, Emad Gamil Khidr, Tohada M Al-Noshokaty, Reem Khaled, Nehal I Rizk, Mohammed S Elballal, Ghadir A Sayed, Mai A Abd-Elmawla, Manar Mohammed El Tabaa, Osama A Mohammed, Alaa Ashraf, Ahmed A El-Husseiny, Heba M Midan, Walaa A El-Dakroury, Mustafa Ahmed Abdel-Reheim, Ahmed S Doghish


Malignant pleural mesothelioma (MPM) is a highly invasive form of lung cancer that adversely affects the pleural and other linings of the lungs. MPM is a very aggressive tumor that often has an advanced stage at diagnosis and a bad prognosis (between 7 and 12 months). When people who have been exposed to asbestos experience pleural effusion and pain that is not explained, MPM should be suspected. After being diagnosed, most MPM patients have a one- to four-year life expectancy. The life expectancy is approximately six months without treatment. Despite the plethora of current molecular investigations, a definitive universal molecular signature has yet to be discovered as the causative factor for the pathogenesis of MPM. MicroRNAs (miRNAs) are known to play a crucial role in the regulation of gene expression at the posttranscriptional level. The association between the expression of these short, non-coding RNAs and several neoplasms, including MPM, has been observed. Although the incidence of MPM is very low, there has been a significant increase in research focused on miRNAs in the past few years. In addition, miRNAs have been found to have a role in various regulatory signaling pathways associated with MPM, such as the Notch signaling network, Wnt/β-catenin, mutation of KRAS, JAK/STAT signaling circuit, protein kinase B (AKT), and Hedgehog signaling pathway. This study provides a comprehensive overview of the existing understanding of the roles of miRNAs in the underlying mechanisms of pathogenic symptoms in MPM, highlighting their potential as viable targets for therapeutic interventions.